AFT Pharmaceuticals Ltd
NZX:AFT
AFT Pharmaceuticals Ltd
AFT Pharmaceuticals Ltd. engages in the development, licensing, and distribution of medical and pharmaceutical products. The firm's segments include New Zealand, Australia, Asia and Rest of World. The firm's products include Crystaderm, Maxigesic, Coco-scalp, Maxiclear, RestoraNail and Myconail, among others. The firm's NasoSURF Nebuliser is in pilot scale production. The firm is focused on conducting clinical for Maxigesic oral dose forms. The firm is also conducting clinical trials of Maxigesic intravenous (IV). Maxigesic PE is a cold and flu variant. Its subsidiary, AFT Pharmaceuticals (AU) Pty Ltd, is engaged in distribution of pharmaceuticals in Australia. Its subsidiary, AFT Pharmaceuticals Singapore Pte Ltd, is engaged in the registration of pharmaceuticals in Singapore. Its subsidiary, AFT Pharmaceuticals (S.E. Asia) Sdn Bhd, is engaged in the distribution of pharmaceuticals in Malaysia.
AFT Pharmaceuticals Ltd. engages in the development, licensing, and distribution of medical and pharmaceutical products. The firm's segments include New Zealand, Australia, Asia and Rest of World. The firm's products include Crystaderm, Maxigesic, Coco-scalp, Maxiclear, RestoraNail and Myconail, among others. The firm's NasoSURF Nebuliser is in pilot scale production. The firm is focused on conducting clinical for Maxigesic oral dose forms. The firm is also conducting clinical trials of Maxigesic intravenous (IV). Maxigesic PE is a cold and flu variant. Its subsidiary, AFT Pharmaceuticals (AU) Pty Ltd, is engaged in distribution of pharmaceuticals in Australia. Its subsidiary, AFT Pharmaceuticals Singapore Pte Ltd, is engaged in the registration of pharmaceuticals in Singapore. Its subsidiary, AFT Pharmaceuticals (S.E. Asia) Sdn Bhd, is engaged in the distribution of pharmaceuticals in Malaysia.
Record Revenue: AFT Pharmaceuticals reported record revenue of $157 million, up 20% for the year, driven mainly by organic growth and strong performance in Australasia.
Profit Growth (Ex-Licensing): Operating profit excluding licensing income increased by 38% to $18.8 million, reflecting underlying business strength despite lumpy licensing payments.
Dividend Initiated: The company declared a dividend of $0.011 per share (11% of net profit after tax), slightly below its longer-term target range due to debt and investment considerations.
Strong OTC Performance: Over-the-counter (OTC) product sales were a major driver, especially in Australia (up 29.7%) and supported margin improvement.
Guidance Provided: Operating profit guidance for FY24 is $22–24 million (excluding licensing income), with up to $6 million additional potential from Maxigesic IV launch in the US, pending FDA approval.
International Expansion: Continued product launches and sales growth in Asia, Europe, and new markets like South Korea and Indonesia, with Asia sales up 24%.
Robust Product Pipeline: 22 new products were launched this year; 68 further launches planned over three years, including expansion in Singapore and Hong Kong.
